WO2002036620A3 - Promoteur specifique de compose relie au facteur de transcription ets, et transactivateurs associes - Google Patents

Promoteur specifique de compose relie au facteur de transcription ets, et transactivateurs associes Download PDF

Info

Publication number
WO2002036620A3
WO2002036620A3 PCT/EP2001/012662 EP0112662W WO0236620A3 WO 2002036620 A3 WO2002036620 A3 WO 2002036620A3 EP 0112662 W EP0112662 W EP 0112662W WO 0236620 A3 WO0236620 A3 WO 0236620A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
nucleic acid
ets
transcription factor
related compound
Prior art date
Application number
PCT/EP2001/012662
Other languages
English (en)
Other versions
WO2002036620A2 (fr
WO2002036620A9 (fr
Inventor
Markus A Rueegg
Alexandre Briguet
Original Assignee
Myocontract Pharmaceutical Res
Markus A Rueegg
Alexandre Briguet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myocontract Pharmaceutical Res, Markus A Rueegg, Alexandre Briguet filed Critical Myocontract Pharmaceutical Res
Priority to EP01992719A priority Critical patent/EP1366072A2/fr
Priority to AU2002219070A priority patent/AU2002219070A1/en
Publication of WO2002036620A2 publication Critical patent/WO2002036620A2/fr
Publication of WO2002036620A9 publication Critical patent/WO2002036620A9/fr
Publication of WO2002036620A3 publication Critical patent/WO2002036620A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des moyens de traitement de maladies, en particulier de maladies musculaires. Elle concerne aussi un acide nucléique pouvant réguler l'expression d'un gène hétérologue et être sélectivement activé par un composé relié au facteur de transcription Ets. Elle concerne encore des constructions, des cellules hôtes comprenant cet acide nucléique, des procédés d'expression recombinante de gènes hétérologues, ainsi que des procédés de criblage et d'identification de composés candidats, possédant une activité régulatrice de transcription, les utilisant. L'invention concerne enfin une protéine de fusion destinée à activer spécifiquement cet acide nucléique, ainsi qu'un nécessaire comprenant l'acide nucléique et la protéine de fusion aux fins d'expression recombinante d'un gène hétérologue.
PCT/EP2001/012662 2000-11-02 2001-10-31 Promoteur specifique de compose relie au facteur de transcription ets, et transactivateurs associes WO2002036620A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01992719A EP1366072A2 (fr) 2000-11-02 2001-10-31 Promoteur specifique de compose relie au facteur de transcription ets, et transactivateurs associes
AU2002219070A AU2002219070A1 (en) 2000-11-02 2001-10-31 Ets-transcription factor related compound specific promoter and transactivators thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00123842 2000-11-02
EP00123842.7 2000-11-02

Publications (3)

Publication Number Publication Date
WO2002036620A2 WO2002036620A2 (fr) 2002-05-10
WO2002036620A9 WO2002036620A9 (fr) 2002-09-19
WO2002036620A3 true WO2002036620A3 (fr) 2003-06-05

Family

ID=8170271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/012662 WO2002036620A2 (fr) 2000-11-02 2001-10-31 Promoteur specifique de compose relie au facteur de transcription ets, et transactivateurs associes

Country Status (3)

Country Link
EP (1) EP1366072A2 (fr)
AU (1) AU2002219070A1 (fr)
WO (1) WO2002036620A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014773A1 (fr) * 1993-11-25 1995-06-01 Alfred Nordheim Nouveaux mutants de facteur de transcription et leur utilisation
WO1996034101A1 (fr) * 1995-04-24 1996-10-31 Medical Research Council Promoteur du gene de l'utrophine
WO1999065929A1 (fr) * 1998-06-16 1999-12-23 The Regents Of The University Of California Les exons 4 et 7 codent pour des domaines distincts de transactivation et de localisation de la chromotine dans le facteur esx
WO2000035474A1 (fr) * 1998-12-11 2000-06-22 Khurana Tejvir S Facteurs de croissance derives de la neurite pour le traitement de dystrophies musculaires
WO2001025461A1 (fr) * 1999-10-04 2001-04-12 Isis Innovation Limited Promoteur du gène utrophine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014773A1 (fr) * 1993-11-25 1995-06-01 Alfred Nordheim Nouveaux mutants de facteur de transcription et leur utilisation
WO1996034101A1 (fr) * 1995-04-24 1996-10-31 Medical Research Council Promoteur du gene de l'utrophine
WO1999065929A1 (fr) * 1998-06-16 1999-12-23 The Regents Of The University Of California Les exons 4 et 7 codent pour des domaines distincts de transactivation et de localisation de la chromotine dans le facteur esx
WO2000035474A1 (fr) * 1998-12-11 2000-06-22 Khurana Tejvir S Facteurs de croissance derives de la neurite pour le traitement de dystrophies musculaires
WO2001025461A1 (fr) * 1999-10-04 2001-04-12 Isis Innovation Limited Promoteur du gène utrophine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AOKI MASAHIRO ET AL: "Nuclear endpoint of Wnt signaling: Neoplastic transformation induced by transactivating lymphoid-enhancing factor 1.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 1, 5 January 1999 (1999-01-05), pages 139 - 144, XP002225124, ISSN: 0027-8424 *
BRIGUET ALEXANDRE ET AL: "The Ets transcription factor GABP is required for postsynaptic differentiation in vivo.", JOURNAL OF NEUROSCIENCE, vol. 20, no. 16, 15 August 2000 (2000-08-15), pages 5989 - 5996, XP002208321, ISSN: 0270-6474 *
BURTON E A ET AL.: "A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE OF USA, vol. 96, no. 24, 23 November 1999 (1999-11-23), pages 14025 - 14030, XP002160373 *
DATABASE EMBL [online] 26 November 1999 (1999-11-26), TINSLEY ET AL: "Homo sapiens partial UTRNB gene for utrophin", XP002208322, Database accession no. AJ250044 *
DATABASE EMBL [online] 30 April 2001 (2001-04-30), BURTON E U ET AL: "Utrophin gene promoter", XP002208323, Database accession no. AX107965 *
FOOS GABRIELE ET AL: "Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 30, 24 July 1998 (1998-07-24), pages 18871 - 18880, XP002225123, ISSN: 0021-9258 *
FRAMPTON J ET AL: "INFLUENCE OF THE V-MYB TRANSACTIVATION DOMAIN ON THE ONCOPROTEIN'S TRANSFORMATION SPECIFICITY", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 12, no. 4, 1993, pages 1333 - 1341, XP001093897, ISSN: 0261-4189 *
OETTGEN ET AL: "PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 2, January 2000 (2000-01-01), pages 1216 - 1225, XP002148117, ISSN: 0021-9258 *
VINCENT KAREN A ET AL: "Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor.", CIRCULATION, vol. 102, no. 18, 31 October 2000 (2000-10-31), pages 2255 - 2261, XP002225125, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
WO2002036620A2 (fr) 2002-05-10
EP1366072A2 (fr) 2003-12-03
WO2002036620A9 (fr) 2002-09-19
AU2002219070A1 (en) 2002-05-15

Similar Documents

Publication Publication Date Title
EP1824977A4 (fr) Nouvel acide nucleique de promoteur issu de la bacterie du genre corynebacterium, cassette d'expression contenant le promoteur et vecteur contenant la cassette, cellule hote comprenant le vecteur et procede d'expression d'un gene au moyen de la cellule
WO2002031134A3 (fr) Nouveaux genes de serine protease apparentes a la dppiv
DK1208211T3 (da) Midler og fremgangsmåder til modificering af genekspression under anvendelse af upolyadenyleret RNA
WO2005100395A3 (fr) Systeme d'expression destine a la preparation de proteines hybrides fc/il-15 et son application
ATE420192T1 (de) Verfahren zur verringerung der antigenität des adeno-assoziierten virus strukturproteins
DE502004008910D1 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
IL157756A (en) Methods for assaying activity of trancriptional control elements
EP1841871A4 (fr) Nouveau promoteur inductible par l-lysine
WO2003020016A3 (fr) Promoteur 7s $g(a) specifique de la semence pour expression de genes chez la plante
WO2004100636A3 (fr) Methode pour modifier la transcription et/ou la translation dans un organisme a des fins therapeutiques, prophylactiques et/ou analytiques
WO2004053088A3 (fr) Calcul genetique faisant appel a la regulation de la transcription combinatoire
WO2002036620A3 (fr) Promoteur specifique de compose relie au facteur de transcription ets, et transactivateurs associes
WO2003016477A3 (fr) Acides nucleiques et proteines de genes recepteurs olfactifs d'insectes or83b et leurs utilisations
AU2002350545A1 (en) Use of the adenoviral e2 late promoter
WO2003031620A1 (fr) Nouveau recepteur des cytokines de classe ii
WO2000068389A3 (fr) Proteines de transport d'auxine
WO2002050104A3 (fr) Methodes et cellules de detection de modulateurs de proteines rgs
WO2003060092A3 (fr) Proteines et genes de l'hydroxylase d'acides gras modifiee
WO2002064802A3 (fr) Éléments régulateurs convenant à l'expression génique
WO2003020913A3 (fr) Acides nucleiques et proteines des genes du recepteur odorant des anopheles gambiae et utilisations correspondantes
WO2004053061A3 (fr) Procedes d'immunotherapie et de diagnostic par ciblage de cellules exprimant des proteines lax
WO2000052179A3 (fr) Syteme de sequence activatrice a mediation assuree par compose de liaison a l'adn
WO2004039985A3 (fr) Expression sélective dans des champignons filamenteux
WO2003020933A1 (fr) Nouvelle proteine mt0039 inhibitrice de serine protease
WO2002053758A3 (fr) Procede de fabrication de proteines heterologues dans un champignon homothallique de la famille sordariaceae

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 2/6, DRAWINGS, REPLACED BY A NEW PAGE 2/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001992719

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001992719

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP